
Predictive Oncology Inc. – NASDAQ:POAI
Predictive Oncology stock price today
Predictive Oncology stock price monthly change
Predictive Oncology stock price quarterly change
Predictive Oncology stock price yearly change
Predictive Oncology key metrics
Market Cap | 4.56M |
Enterprise value | N/A |
P/E | -0.82 |
EV/Sales | -0.66 |
EV/EBITDA | 0.03 |
Price/Sales | 9.32 |
Price/Book | 0.93 |
PEG ratio | -0.01 |
EPS | -3.65 |
Revenue | 1.95M |
EBITDA | -13.87M |
Income | -14.78M |
Revenue Q/Q | 74.92% |
Revenue Y/Y | 36.97% |
Profit margin | -1802.31% |
Oper. margin | -1159.36% |
Gross margin | 65.84% |
EBIT margin | -1159.36% |
EBITDA margin | -708.06% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freePredictive Oncology stock price history
Predictive Oncology stock forecast
Predictive Oncology financial statements
Jun 2023 | 490.11K | -3.92M | -800.51% |
---|---|---|---|
Sep 2023 | 715.05K | -3.16M | -442.41% |
Dec 2023 | 335.03K | -3.47M | -1037.32% |
Mar 2024 | 419.64K | -4.21M | -1005.33% |
2025 | 113.2M | 28.10M | 24.83% |
---|
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 20967006 | 6.26M | 29.87% |
---|---|---|---|
Sep 2023 | 18166868 | 6.51M | 35.86% |
Dec 2023 | 14417249 | 6.14M | 42.63% |
Mar 2024 | 10601187 | 6.54M | 61.76% |
Jun 2023 | -3.57M | -259.10K | 0 |
---|---|---|---|
Sep 2023 | -3.10M | -3.92K | 260.22K |
Dec 2023 | -3.08M | 7.29K | -111.32K |
Mar 2024 | -3.41M | -3.03K | -112.37K |
Predictive Oncology alternative data
Aug 2023 | 31 |
---|---|
Sep 2023 | 31 |
Oct 2023 | 31 |
Nov 2023 | 31 |
Dec 2023 | 31 |
Jan 2024 | 31 |
Feb 2024 | 31 |
Mar 2024 | 31 |
Apr 2024 | 31 |
May 2024 | 34 |
Jun 2024 | 34 |
Jul 2024 | 34 |
Predictive Oncology other data
Period | Buy | Sel |
---|---|---|
Nov 2022 | 10000 | 0 |
Dec 2022 | 19795 | 0 |
Sep 2023 | 0 | 10000 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Option | MYERS ROBERT L officer: CHIEF FI.. | Common Stock | 1,667 | N/A | N/A | ||
Sale | NUZUM CHARLES LEE SR director | Common Stock | 10,000 | $3.04 | $30,390 | ||
Purchase | HANDLEY DANIEL E director | Common Stock | 6,000 | $0.41 | $2,460 | ||
Purchase | VENNARE RAYMOND F director | Common Stock | 400 | $0.52 | $208 | ||
Purchase | VENNARE RAYMOND F director | Common Stock | 4,600 | $0.52 | $2,374 | ||
Purchase | MYERS ROBERT L officer: CHIEF FI.. | Common Stock | 8,795 | $0.57 | $5,004 | ||
Purchase | HANDLEY DANIEL E director | Common Stock | 10,000 | $0.36 | $3,580 | ||
Option | MYERS ROBERT L officer: CHIEF FI.. | Common Stock | 33,333 | N/A | N/A | ||
Option | MYERS ROBERT L officer: CHIEF FI.. | Restricted Stock Units | 33,333 | N/A | N/A | ||
Purchase | HANDLEY DANIEL E director | Common Stock | 2,550 | $0.38 | $956 |
Quarter | Transcript |
---|---|
Q1 2024 15 May 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 1 Apr 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 14 Nov 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 10 Aug 2023 | Q2 2023 Earnings Call Transcript |
Insider | Compensation |
---|---|
Mr. Robert L. Myers (1955) Chief Financial Officer & Sec. | $327,840 |
Mr. J. Melville Engle (1950) Chairman & Chief Executive Officer | $3,000 |
-
What's the price of Predictive Oncology stock today?
One share of Predictive Oncology stock can currently be purchased for approximately $0.9.
-
When is Predictive Oncology's next earnings date?
Unfortunately, Predictive Oncology's (POAI) next earnings date is currently unknown.
-
Does Predictive Oncology pay dividends?
No, Predictive Oncology does not pay dividends.
-
How much money does Predictive Oncology make?
Predictive Oncology has a market capitalization of 4.56M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 18.24% to 1.78M US dollars.
-
What is Predictive Oncology's stock symbol?
Predictive Oncology Inc. is traded on the NASDAQ under the ticker symbol "POAI".
-
What is Predictive Oncology's primary industry?
Company operates in the Healthcare sector and Medical - Instruments & Supplies industry.
-
How do i buy shares of Predictive Oncology?
Shares of Predictive Oncology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Predictive Oncology's key executives?
Predictive Oncology's management team includes the following people:
- Mr. Robert L. Myers Chief Financial Officer & Sec.(age: 70, pay: $327,840)
- Mr. J. Melville Engle Chairman & Chief Executive Officer(age: 75, pay: $3,000)
-
How many employees does Predictive Oncology have?
As Jul 2024, Predictive Oncology employs 34 workers, which is 10% more then previous quarter.
-
When Predictive Oncology went public?
Predictive Oncology Inc. is publicly traded company for more then 15 years since IPO on 3 May 2010.
-
What is Predictive Oncology's official website?
The official website for Predictive Oncology is predictive-oncology.com.
-
Where are Predictive Oncology's headquarters?
Predictive Oncology is headquartered at 2915 Commers Drive, Eagan, MN.
-
How can i contact Predictive Oncology?
Predictive Oncology's mailing address is 2915 Commers Drive, Eagan, MN and company can be reached via phone at +65 13894800.
Predictive Oncology company profile:

Predictive Oncology Inc.
predictive-oncology.comNASDAQ
34
Medical - Instruments & Supplies
Healthcare
Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.
Eagan, MN 55121
CIK: 0001446159
ISIN: US74039M3097
CUSIP: 74039M200